- Home
- SYBT vs AGIO Comparison
SYBT vs AGIO Comparison
Compare SYBT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- AGIO
- Stock Information
- Founded
- SYBT 1904
- AGIO 2007
- Country
- SYBT United States
- AGIO United States
- Employees
- SYBT N/A
- AGIO N/A
- Industry
- SYBT Major Banks
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- AGIO Health Care
- Exchange
- SYBT Nasdaq
- AGIO Nasdaq
- Market Cap
- SYBT 2.3B
- AGIO 2.1B
- IPO Year
- SYBT N/A
- AGIO 2013
- Fundamental
- Price
- SYBT $74.21
- AGIO $36.42
- Analyst Decision
- SYBT Hold
- AGIO Buy
- Analyst Count
- SYBT 3
- AGIO 6
- Target Price
- SYBT $83.67
- AGIO $57.00
- AVG Volume (30 Days)
- SYBT 86.2K
- AGIO 762.4K
- Earning Date
- SYBT 10-22-2025
- AGIO 10-30-2025
- Dividend Yield
- SYBT 1.64%
- AGIO N/A
- EPS Growth
- SYBT 22.18
- AGIO N/A
- EPS
- SYBT 4.35
- AGIO 11.13
- Revenue
- SYBT $364,546,000.00
- AGIO $40,875,000.00
- Revenue This Year
- SYBT $16.83
- AGIO $23.66
- Revenue Next Year
- SYBT $5.12
- AGIO $143.65
- P/E Ratio
- SYBT $17.36
- AGIO $3.35
- Revenue Growth
- SYBT 11.32
- AGIO 30.57
- 52 Week Low
- SYBT $57.12
- AGIO $23.42
- 52 Week High
- SYBT $83.83
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- SYBT 36.16
- AGIO 47.14
- Support Level
- SYBT $76.66
- AGIO $35.72
- Resistance Level
- SYBT $77.82
- AGIO $37.18
- Average True Range (ATR)
- SYBT 1.75
- AGIO 1.58
- MACD
- SYBT -0.70
- AGIO -0.14
- Stochastic Oscillator
- SYBT 4.42
- AGIO 44.29
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.